You just read:

New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment

News provided by

Janssen Pharmaceuticals, Inc.

06 Dec, 2016, 08:00 ET